别名 Cas-Br-M (murine) ecotropic retroviral transforming sequence b、Cas-Br-M (murine) ectropic retroviral transforming sequence b、Casitas B-lineage lymphoma proto-oncogene b + [10] |
简介 E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity). |
靶点 |
作用机制 Cbl-b抑制剂 |
非在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 Cbl-b抑制剂 |
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 Cbl-b抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-02-10 |
开始日期2023-08-22 |
申办/合作机构- |
开始日期2023-08-22 |
申办/合作机构- |